If any industry has been under pressure over the past year or so, it has been biotechnology. While there are some positives for the industry, it still faces some definite headwinds as well. Weak prescription data and long-term competitive/pricing constraints are somewhat balanced out with some newfound industry momentum and more positive news flow.
A massive new Jefferies research report reminds investors that as a rule the first quarter is traditionally slower for the biotechs, and the report noted:
First quarter tends to be soft and based on our prescription analysis, we see some modest misses across the boards but nothing that would dampen near-term enthusiasm, especially given a recent string of positive data points and product approvals.
The analysts feel that three top companies in their coverage universe, two of which are rated Buy, can beat the current top-line estimates.
This stock trades at an astounding multiple of less than seven times estimated 2017 estimated profits. Gilead Sciences Inc. (NASDAQ: GILD) discovers, develops and commercializes medicines in areas of unmet medical need in North America, South America, Europe and the Asia-Pacific. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread and Hepsera products for the treatment of liver disease.
The stock was hit on 2017 guidance, which was much lower than expected on diminishing hepatitis C revenue. However, the analyst is positive on the company’s HIV franchise going forward. It also cited new drug filings this year as potential catalysts
Jefferies thinks that a spin-off of the hepatitis C silo of the business is entirely possible, as the declining predictable revenues have weighed on the company’s overall valuation. While not a given, a transaction could improve long-term growth and improve the positive impact of a future acquisition or pipeline success.
Investors receive a 3.12% dividend. The Jefferies price target for the stock is $82, and the Wall Street consensus figure is $79.06. Shares closed Friday at $66.58.
This top mid-cap is rumored to be in the sights of a larger biotech company. Incyte Corp. (NASDAQ: INCY) has a current validated approach in hematology-oncology, and there’s reason to believe the three wholly owned clinical-stage assets the company has could drive several billion in revenue, something important for an acquiring company looking to acquire assets. Many on Wall Street are bullish on the company’s rich pipeline of small molecule therapies in all stages of development, and they see the company as a key player in the cancer space.
Incyte focuses on the discovery, development and commercialization of proprietary therapeutics in oncology. It offers Jakafi for the treatment of myelofibrosis and polycythemia vera cancers. Its clinical stage products include ruxolitinib cream, which is in Phase 2 clinical trial for the treatment of alopecia areata; and INCB52793, which is in Phase 1/2 for the treatment of advanced malignancies. The company’s clinical stage products also comprise baricitinib, which is in Phase 3 trial for rheumatoid arthritis, as well as a completed Phase 2 trial for psoriasis and diabetic nephropathy.
Jefferies has a $165 price target, and the consensus price objective is $149. Shares ended Friday at $110.84.
Jefferies only rates this stock as a Hold but still think it can beat the first-quarter top-line estimates. Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has been a performance monster over the past two years, and most Wall Street firms expect it to stay one. The company is focused on the development of therapeutic human antibodies for the treatment of eye disorders, hypercholesterolemia, cancer, inflammation and other diseases.
Regeneron’s product sales are driven principally by its VEGF inhibitor Eylea, which is approved for use in wet age-related macular degeneration and diabetic macular edema, and by Praluent for the treatment of hypercholesterolemia.
The company recently reported that evinacumab has received FDA breakthrough therapy designation for homozygous familial hypercholesterolemia. Regeneron also reported positive interim Phase 2 results for evinacumab in such patients, and it is currently planning a Phase 3 trial for Eikon.
The $385 Jefferies price target is less than the consensus target of $423.23. Shares closed Friday at $380.55.
These three top companies could get an outstanding lift should they come in with revenues above current estimates. All three stocks are best suited for aggressive growth accounts with a large degree of risk tolerance.